Danish Retail Group Blacklists Cosmetics With PFAS; Australian Animal-Testing Ban; More Cosmetics News

Cosmetics containing fluorinated compounds are no longer welcome in Coop Denmark’s 1,050 stores or its e-commerce platform. Meanwhile, consumer group BEUC proposes changes to the European Cosmetics Regulation to address endocrine-disrupting chemicals, and Australia passes legislation to bar new, cosmetics-only chemicals from market if their safety substantiation relies on animal testing.

3d render of Europe map Earth globe

The leading consumer goods retailer in Denmark, Coop Danmark A/S, announced March 9 that it will no longer be purchasing cosmetic products containing per- and polyfluoroalkyl substances (PFAS), including from international brands, due to concerns about cancer, endocrine disruption and other health risks linked to the ingredient group. (Also see "Personal-Care Ingredient News In Brief: UC Berkeley Study Makes Waves; PFAS In Cosmetics; More" - HBW Insight, 11 December, 2018.) “We have a great focus on protecting our customers from exposure to chemical substances that can contribute to a harmful cocktail effect. By taking the lead, we hope that the entire international beauty industry can be encouraged to find better alternatives,” says Coop Quality Manager Malene Teller Blume. The decision, effective immediately, means that PFAS-containing cosmetics will vanish by mid-September from coop.dk and Coop retail chains – including Kvickly, SuperBrugsen, Dagli’Brugsen and subsidiaries fakta A/S and Irma A/S – which in sum account for 1,050 stores across Denmark and DKK 50bn in annual turnover, according to the release.

European consumer-advocacy group BEUC is convinced that changes are needed to the Cosmetics Regulation in order for endocrine-disrupting chemical (EDC)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

UK Org ‘Snapshot’ Sampling: Most Third-Party Beauty On Four Ecommerce Sites ‘Likely’ Counterfeit

 

UK consumer advocacy organization finds more than two-thirds of 34 skin care and makeup products it purchased from third party sellers on major ecommerce sites are likely fake.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

US FDA: No Replacement Yet For Animal Methods In Testing Systemic Effects Of Sunscreens

 
• By 

While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.

EU Proposal To Simplify Hazardous Chemical Rules For Cosmetics ‘Step In Right Direction’ - Industry

 

The European Commission’s Simplification Omnibus published July 8 is ‘step in right direction’ for streamlining processes and providing more legal certainty and predictability for regulations addressing cosmetics, says Cosmetics Europe.

More from Policy & Regulation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By 

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.